Treatment of Group I Pulmonary Arterial Hypertension with Carvedilol Is Safe

摘要

The principal treatment strategy for patients with pulmonary artery hypertension (PAH) is the use of medications targeting the pulmonary vasculature . Despite several classes of available therapy for the treatment of PAH, some of which can improve cardiac function, patients continue to die of right heart failure (RHF) and additional therapies are needed. We have previously proposed that the dysfunctional right ventricle (RV) should be a treatment target in patients with PAH . β-Adrenergic receptor (BAR) blockade has been a mainstay of congestive left heart failure treatment for years and yet, despite some initial prospective safety data , BAR blockers are infrequently used in patients with PAH and RV dysfunction.